Point72 Asset Management L.P. Has $2.74 Million Position in Cryoport, Inc. (NASDAQ:CYRX)

Point72 Asset Management L.P. decreased its position in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 16.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 352,680 shares of the company's stock after selling 67,220 shares during the period. Point72 Asset Management L.P. owned 0.71% of Cryoport worth $2,744,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of CYRX. SG Americas Securities LLC increased its holdings in shares of Cryoport by 44.8% in the fourth quarter. SG Americas Securities LLC now owns 146,789 shares of the company's stock valued at $1,142,000 after purchasing an additional 45,430 shares during the period. Rhumbline Advisers grew its holdings in Cryoport by 2.9% in the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock valued at $492,000 after purchasing an additional 1,764 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Cryoport by 1,464.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 305,237 shares of the company's stock valued at $2,475,000 after acquiring an additional 285,726 shares during the last quarter. Graham Capital Management L.P. lifted its holdings in shares of Cryoport by 24.9% in the fourth quarter. Graham Capital Management L.P. now owns 28,460 shares of the company's stock valued at $221,000 after purchasing an additional 5,667 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Cryoport by 8.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 60,003 shares of the company's stock worth $467,000 after purchasing an additional 4,902 shares in the last quarter. 92.90% of the stock is owned by institutional investors and hedge funds.

Cryoport Stock Down 2.9%

CYRX traded down $0.18 during trading on Monday, hitting $6.04. The company had a trading volume of 253,099 shares, compared to its average volume of 544,154. The company has a market cap of $302.83 million, a PE ratio of -1.79 and a beta of 1.92. Cryoport, Inc. has a 1-year low of $4.58 and a 1-year high of $11.64. The business has a 50-day moving average of $5.93 and a 200-day moving average of $6.81. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32.

Cryoport (NASDAQ:CYRX - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The firm had revenue of $41.04 million for the quarter, compared to analysts' expectations of $56.19 million. As a group, analysts forecast that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Jerrell Shelton sold 4,620 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the sale, the chief executive officer now owns 765,399 shares in the company, valued at $4,814,359.71. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders sold 19,830 shares of company stock worth $118,353. 10.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Morgan Stanley dropped their price objective on Cryoport from $8.00 to $7.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. UBS Group increased their target price on Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Guggenheim reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Cryoport in a research note on Wednesday, April 16th. Needham & Company LLC restated a "buy" rating and issued a $11.00 price target on shares of Cryoport in a report on Thursday, May 8th. Finally, Roth Mkm reissued a "buy" rating and issued a $15.00 target price on shares of Cryoport in a research note on Tuesday, April 1st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $11.00.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.